Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, and Astellas Scientific and Medical Affairs Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced a multi-year research collaboration to explore new ideas and ways to improve the health and well-being of patients and members.
The two companies will bring together researchers and health care experts from both companies to study key issues and develop ways to reduce inefficiencies in the management of oncology, urology and immunology conditions.
“This research collaboration will produce knowledge in important therapeutic areas for our key population,” said William Fleming, Pharm.D., President of Humana Pharmacy Solutions. “With about 77 percent 1 of all cancers being diagnosed in people 55 years of age and older, and 1 in 2 2 males and 1 in 3 females at risk for developing cancer in their lifetime, this partnership will serve to develop an important body of knowledge that will meaningfully advance the work of our respective companies.”
“We believe that the combination of Humana’s experience with affordable senior health care and Astellas’ commitment to advancements in healthcare, particularly in the areas of oncology, urology and transplantation will help improve the lifelong well-being of patients,” said Jeffrey Bloss, M.D., Vice President, Astellas Scientific and Medical Affairs Inc. “Through this important collaboration, we’ll use clinical data to conduct comparative effectiveness research to evaluate ways to improve healthcare and health outcomes for patients.”About Humana Humana Inc., headquartered in Louisville, Ky., is a leading health care company that offers a wide range of insurance products and health and wellness services that incorporate an integrated approach to lifelong well-being. By leveraging the strengths of its core businesses, Humana believes it can better explore opportunities for existing and emerging adjacencies in health care that can further enhance wellness opportunities for the millions of people across the nation with whom the company has relationships.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts